期刊文献+

达英-35和二甲双胍在多囊卵巢综合征治疗中的效果观察

Efficacy of Ethinyl estradiol cyproterone tablets and metformin treatment of polycystic ovary syndrome
原文传递
导出
摘要 目的探讨达英-35和二甲双胍治疗多囊卵巢综合征(PCOS)的疗效。方法将驻马店市第一人民医院2013年6月—2014年8月收治的PCOS患者94例,随机分成甲组(48例)、乙组(46例),分别采用达英-35联合二甲双胍治疗、单纯达英-35治疗。结果治疗后甲组体重指数(BMI)、黄体生成素(LH)、卵泡刺激素(FSH)、LH/FSH、睾酮(T)降低幅度明显大于乙组,差异均有统计学意义(P<0.05),而两组FSH、FIN无显著变化(P>0.05),甲组治疗后稀发、痤疮、多毛、卵巢体积增大等改善情况均优于乙组,差异有统计学意义(P<0.05)。结论达英-35联合二甲双胍治疗PCOS疗效好,可明显改善患者临床症状与体征。 Objective To investigate the effect of cyproterone ethinyl estradiol tablets ( Diane-35 ) combined with met-formin in treatment of polycystic ovary syndrome(PCOS) is. Methods PCOS patients in our hospital in June 2013 August 2014 admitted 94 eases were randomly divided into Group A(48 cases) , B(46 cases) , respectively Diane-35 combined with metformin therapy alone TAIE -35 therapy. Results After treatment, Group A body mass index( BMI), luteinizing hormone (LH) , follicle stimulating hormone (FSH) , LH / FSH, testosterone (T) was significantly greater than the reduction in the Group B, the differences were statistically significant (P 〈 0. 05 ) , while the two FSH, FIN no significant change(P 〉0. 05) , thin hair treatment after the First Division, acne, hirsutism, ovarian volume increases and so improve the situation were has than B, the difference was statistically significant ( P 〈 0. 05 ). Conclusion Diane-35 Joint PCOS metformin good effect, can significantly improve patients" clinical symptoms and signs.
作者 王冬梅
出处 《医药论坛杂志》 2015年第1期46-47,共2页 Journal of Medical Forum
关键词 多囊卵巢综合征 达英-35 二甲双胍 polycystic ovary syndrome Diane-35 metformin
  • 相关文献

参考文献5

二级参考文献58

  • 1胡敏,侯丽辉,吴效科.瘦素与多囊卵巢综合征的研究进展[J].中国妇幼健康研究,2006,17(2):125-128. 被引量:9
  • 2Rotterdam ESHRE/ASRM -Sponsored PCOS consensusworkshopgroup. Revised 2003consensus on diagnostic criteria and long - termhealth risks related to polycystic ovary syndrome(PCOS) [ J ], Hum Re-prod, 2004,19 ( 1 ) :41-47.
  • 3Hardiman P, Pillag oc, Atioma W. Polycytic ovarg syndrome and endometrial carcinma [ J ]. Lancet, 2003,361 (9371) :1801-1802.
  • 4The Rotterdam ESHRE/ ASRM Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystie ovary syndrome (PCOS)[J]. Hum Reprod,2004,19(1) :41-42.
  • 5Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneek Study [J]. Diabetes, 1998,47 (10) :1643-1649.
  • 6Costello M F, Eolen J A. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome[J]. Fertil Steril, 2003,79 (1) : 1-13.
  • 7Holick MF.Vitamin D deficiency[J]. New Engl J Med,2007,357:266-281.
  • 8Lerchbaum E,Obermayer-Pietsch B.Vitamin D and fertility:a systematic review[J]. Eu J Endocrinol,2012,166:765-778.
  • 9Patra SK,Nasrat H,Goswami B,et al.Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome[J]. Diabetes Metab Syndr,2012,6:146-149.
  • 10Wehr E,Pieber TR,Obemayer-Pietsch B.Effect of vitamin D3treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women:apilot study[J]. J Endocrinol Invest,2011,34:757-763.

共引文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部